[HTML][HTML] The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers

I Cavallari, F Ciccarese, E Sharova, L Urso… - Cancers, 2021 - mdpi.com
Simple Summary MicroRNAs (miRNAs) are small RNA molecules that regulate gene
expression by blocking translation or inducing degradation of specific gene transcripts. The …

An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer

H Qayoom, NA Wani, B Alshehri, MA Mir - Future Oncology, 2021 - Future Medicine
Triple-negative breast cancer (TNBC) is the most complex, aggressive and fatal subtype of
breast cancer. Owing to the lack of targeted therapy and heterogenic nature of TNBC …

[HTML][HTML] A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer

S Wu, J Lu, H Zhu, F Wu, Y Mo, L Xie, C Song, L Liu… - Cancer Letters, 2024 - Elsevier
Among patients with triple-negative breast cancer (TNBC), distant metastasis is the leading
cause of death. Our previous studies have shown that TNBC progression is greatly …

[HTML][HTML] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

H Kumar, NV Gupta, R Jain… - Journal of Advanced …, 2023 - Elsevier
Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …

[HTML][HTML] Addiction of cancer stem cells to MUC1-C in triple-negative breast cancer progression

N Yamashita, D Kufe - International Journal of Molecular Sciences, 2022 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment
options. TNBC progression is associated with expansion of cancer stem cells (CSCs). Few …

[HTML][HTML] Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

N Srivastava, SS Usmani, R Subbarayan… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is one of the deadliest subtypes of breast cancer (BC)
for its high aggressiveness, heterogeneity, and hypoxic nature. Based on biological and …

[HTML][HTML] Breast cancer stem cell membrane biomarkers: therapy targeting and clinical implications

I Conde, AS Ribeiro, J Paredes - Cells, 2022 - mdpi.com
Breast cancer is the most common malignancy affecting women worldwide. Importantly,
there have been significant improvements in prevention, early diagnosis, and treatment …

[HTML][HTML] Oncogenic and stemness signatures of the high-risk HCMV strains in breast cancer progression

R El Baba, S Pasquereau, S Haidar Ahmad… - Cancers, 2022 - mdpi.com
Simple Summary Lately, human cytomegalovirus (HCMV) has been progressively
implicated in carcinogenesis alongside its oncomodulatory impact. CMV-Transformed …

[HTML][HTML] Engineered vitamin E-tethered non-immunogenic facial lipopeptide for developing improved siRNA based combination therapy against metastatic breast …

AM Mallick, A Biswas, S Mishra, S Jadhav… - Chemical …, 2023 - pubs.rsc.org
RNA interference based therapeutic gene silencing is an emerging platform for managing
highly metastatic breast cancer. Cytosolic delivery of functional siRNA remains the key …

[HTML][HTML] The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human SORT1-positive ovarian and triple-negative breast cancer stem-like cells

M Demeule, C Charfi, JC Currie, A Zgheib… - Pharmaceutics, 2022 - mdpi.com
Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and
chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1) …